New drug combination before surgery for advanced throat cancer
Part of Cancer clinical trials.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hypopharyngeal squamous cell carcinoma (a type of throat cancer).
- Your cancer is locally advanced (stage III or IV) but has not spread to other body parts, and it can be surgically removed.
- You have not received any previous treatment (chemotherapy, radiation, or surgery) for this current cancer.
- You are in generally good health (able to carry out daily activities with little to no assistance).
- You do not have serious infections, autoimmune diseases, or long-term lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests two new cancer-fighting drugs together to treat advanced squamous cell carcinoma (a common type of head and neck cancer) in patients who cannot tolerate or refuse platinum-based chemotherapy. The goal is to see if this combination can shrink or control the cancer.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Hear when a new Hypopharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.